These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788 [TBL] [Abstract][Full Text] [Related]
3. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection. Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920 [TBL] [Abstract][Full Text] [Related]
5. Genetic characterization and pathogenicity assessment of highly pathogenic H5N1 avian influenza viruses isolated from migratory wild birds in 2011, South Korea. Kwon HI; Song MS; Pascua PN; Baek YH; Lee JH; Hong SP; Rho JB; Kim JK; Poo H; Kim CJ; Choi YK Virus Res; 2011 Sep; 160(1-2):305-15. PubMed ID: 21782862 [TBL] [Abstract][Full Text] [Related]
6. Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. Itoh Y; Yoshida R; Shichinohe S; Higuchi M; Ishigaki H; Nakayama M; Pham VL; Ishida H; Kitano M; Arikata M; Kitagawa N; Mitsuishi Y; Ogasawara K; Tsuchiya H; Hiono T; Okamatsu M; Sakoda Y; Kida H; Ito M; Quynh Mai L; Kawaoka Y; Miyamoto H; Ishijima M; Igarashi M; Suzuki Y; Takada A PLoS Pathog; 2014 Jun; 10(6):e1004192. PubMed ID: 24945244 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes. Wu J; Zhang F; Fang F; Chang H; Wang F; Yang Z; Sun B; Chen Z Vaccine; 2010 Mar; 28(15):2775-81. PubMed ID: 20117261 [TBL] [Abstract][Full Text] [Related]
9. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027 [TBL] [Abstract][Full Text] [Related]
10. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041 [TBL] [Abstract][Full Text] [Related]
11. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets. Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184 [TBL] [Abstract][Full Text] [Related]
12. Characterization of highly pathogenic H5N1 avian influenza viruses isolated from poultry markets in central China. Chen J; Fang F; Yang Z; Liu X; Zhang H; Zhang Z; Zhang X; Chen Z Virus Res; 2009 Dec; 146(1-2):19-28. PubMed ID: 19720095 [TBL] [Abstract][Full Text] [Related]
13. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735 [TBL] [Abstract][Full Text] [Related]
14. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168 [TBL] [Abstract][Full Text] [Related]
15. Genetic and biological characterization of avian influenza H5N1 viruses isolated from wild birds and poultry in Western Siberia. Sharshov K; Romanovskaya A; Uzhachenko R; Durymanov A; Zaykovskaya A; Kurskaya O; Ilinykh P; Silko N; Kulak M; Alekseev A; Zolotykh S; Shestopalov A; Drozdov I Arch Virol; 2010 Jul; 155(7):1145-50. PubMed ID: 20432047 [TBL] [Abstract][Full Text] [Related]
16. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Lu X; Edwards LE; Desheva JA; Nguyen DC; Rekstin A; Stephenson I; Szretter K; Cox NJ; Rudenko LG; Klimov A; Katz JM Vaccine; 2006 Nov; 24(44-46):6588-93. PubMed ID: 17030078 [TBL] [Abstract][Full Text] [Related]
17. Characterization of an H5N1 avian influenza virus from Taiwan. Lee MS; Deng MC; Lin YJ; Chang CY; Shieh HK; Shiau JZ; Huang CC Vet Microbiol; 2007 Oct; 124(3-4):193-201. PubMed ID: 17512143 [TBL] [Abstract][Full Text] [Related]
18. Characterization of duck H5N1 influenza viruses with differing pathogenicity in mallard (Anas platyrhynchos) ducks. Tang Y; Wu P; Peng D; Wang X; Wan H; Zhang P; Long J; Zhang W; Li Y; Wang W; Zhang X; Liu X Avian Pathol; 2009 Dec; 38(6):457-67. PubMed ID: 19937535 [TBL] [Abstract][Full Text] [Related]
19. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine. Yang P; Tang C; Luo D; Zhan Z; Xing L; Duan Y; Jia W; Peng D; Liu X; Wang X Vet Microbiol; 2010 Nov; 146(1-2):17-23. PubMed ID: 20888151 [TBL] [Abstract][Full Text] [Related]
20. Isolation of a genotypically unique H5N1 influenza virus from duck meat imported into Japan from China. Mase M; Eto M; Tanimura N; Imai K; Tsukamoto K; Horimoto T; Kawaoka Y; Yamaguchi S Virology; 2005 Aug; 339(1):101-9. PubMed ID: 15964604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]